Symbiomix Therapeutics, LLC Email Format
PharmaceuticalsNew Jersey, United States2-10 Employees
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing medicines to treat prevalent gynecological infections that can have serious health consequences. The Newark, New Jersey-based company, founded in 2012, operates additional offices in Maryland and Connecticut and belongs to the pharmaceutical manufacturing sector. One of its products, Solosec (secnidazole oral granules), is intended for the treatment of bacterial vaginosis, and the company filed a new drug application with the U.S. Food and Drug Administration in January 2017. In February 2017, David L. Stern was appointed as CEO. The organization remains a relatively small enterprise focusing on developing therapies for gynecological infections and related health outcomes.